Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Strong 2Q And Fresh UK Investment Signal Few Brexit Blues at GSK

Executive Summary

GlaxoSmithKline reported a strong second quarter and along with its core EPS guidance upgrade, this adds momentum to its post-Brexit vote boost.

Advertisement

Related Content

3Q Pharma Results Preview: Novartis, Merck, Lilly, Bayer, GSK, Bristol, Amgen, Sanofi
UK Pharma's 'Brexit Playbook' Might Envision New Regulator Roles
GSK And Google To Invest £540m In UK-Headquartered Bioelectronics JV
GSK Foresees Return To Emerging Markets Growth
GSK's Vaccines Chief Slaoui To Follow Witty Out The Door
GSK Ups Ante In Triple COPD Therapy Race But Payers Wary
What’s On CEO Andrew Witty’s To-Do List Before Exiting GSK

Topics

Advertisement
UsernamePublicRestriction

Register

SC096996

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel